Outset Medical, Inc. Stock Price, News & Analysis

Outset Medical, Inc. (Nasdaq: OM) announced the completion of its public offering, selling 2,945,864 shares at $53.50 each, alongside 3,890,723 shares from certain stockholders. The offering included 891,728 additional shares due to underwriter options, yielding net proceeds of approximately $149.7 million for Outset, after costs. The offering was managed by Morgan Stanley, BofA Securities, and Goldman Sachs, among others. Outset aims to leverage these funds for advancing its Tablo Hemodialysis System, which simplifies dialysis for patients and providers.

Outset Medical's Tablo Hemodialysis System has been awarded as one of seven winners in Round 2 of the KidneyX COVID-19 Kidney Care Challenge by the U.S. Department of Health and Human Services and the American Society of Nephrology. This recognition highlights Tablo's innovative solution for dialysis amid the pandemic, aimed at reducing transmission risks of COVID-19. With features like remote monitoring through TabloHub, Tablo simplifies dialysis, enhances patient care, and allows flexibility in resource management. The KidneyX Challenge has a total prize pool of $300,000 for innovative kidney care solutions.

Outset Medical, Inc. (Nasdaq: OM) has announced the pricing of a public offering of 2,500,000 shares of its common stock at $53.50 per share, alongside 3,444,859 shares sold by existing stockholders. Additionally, underwriters have a 30-day option to purchase up to 891,728 shares. The offering is set to close on April 13, 2021, subject to customary conditions. Morgan Stanley, BofA Securities, and Goldman Sachs are leading the underwriting effort. A registration statement related to this offering is effective with the SEC.

Outset Medical, Inc. (Nasdaq: OM) announced a proposed underwritten public offering of 2,500,000 shares of common stock, with an additional 750,000 shares option for underwriters. This offering is under market conditions and is subject to SEC registration. Morgan Stanley, BofA Securities, and Goldman Sachs are the lead managers for the offering. The funds raised are aimed at reducing dialysis costs and complexity through their innovative Tablo Hemodialysis System. However, completion of the offering is uncertain, depending on market conditions and other factors.

Outset Medical, Inc. (Nasdaq: OM) has appointed Andrea Saia to its board of directors, aiming to enhance its consumer focus and expand the home dialysis market. Saia, a global business leader with 40 years of experience, previously worked with major brands like Novartis and Procter & Gamble. CEO Leslie Trigg emphasized her expertise in the consumer health landscape as vital for Outset's growth. The company also announced that Ali Osman has stepped down from the board after contributing to its recent growth.

Outset Medical, Inc. (Nasdaq: OM) reported significant financial growth for the fourth quarter and full year ended December 31, 2020. Fourth-quarter revenue reached $17.2 million, a 143% increase year-over-year, while full-year revenue was $49.9 million, a 231% increase. Despite this growth, the company incurred a net loss of ($32.0) million in Q4 and ($79.3) million for the full year. Outset projects 2021 revenue between $89 million and $94 million, indicating a strong outlook with 78% to 88% anticipated growth over 2020.

Outset Medical, Inc. (Nasdaq: OM) will release its financial results for Q4 and the full year of 2020 on March 9, 2021, after market close. A conference call led by CEO Leslie Trigg and CFO Rebecca Chambers will discuss financial and operating results at 2:00 PM PT (5:00 PM ET). Investors can participate via phone or listen to a live and archived webcast on Outset's website. Outset is recognized for its Tablo Hemodialysis System, designed to streamline dialysis care and facilitate treatment at home or in clinics.

Outset Medical, Inc. (Nasdaq: OM) has appointed Karen Drexler to its board of directors, enhancing its leadership in the medtech field. Drexler, recognized as a top corporate director by Women Inc. magazine, brings valuable experience from notable companies like ResMed and Sandstone Diagnostics. Her expertise in data analytics and consumer-centric approaches aligns with Outset's strategies for its Tablo System, aimed at improving patient experiences in dialysis. Additionally, TJ Carella has stepped down from the board after a decade of impactful contributions.

Outset Medical, Inc. (Nasdaq: OM) announced an underwritten public offering of 4,000,000 shares at $53.00 per share, exclusively by certain stockholders. The underwriters also have a 30-day option for an additional 600,000 shares. Outset will not receive any proceeds from this offering, which is expected to close on December 7, 2020. BofA Securities, Morgan Stanley, and Goldman Sachs & Co. LLC are leading the offering.
This press release emphasizes Outset's innovative dialysis technology and future growth potential.